SBI heads the Irish ELIXIR node, where Prof Walter Kolch heads the Irish node and Dr. Colm Ryan serves as Deputy HoN. Read more about this initiative here: https://www.elixir-europe.org/
SFI-EMBL Partnership Initiative
175,000 children develop cancer every day, and current treatments often result in significant long term side effects. There is therefore clearly a need for improved therapies and diagnotiscs in young cancer patients. In partnership with EMBL, SBI has developed a new initiative to seek funding for a 5 year program to address this gap in childhood cancer research. For more information and opportunities related to this initiative, please contact us (firstname.lastname@example.org).
SBI runs the TopMed10 Marie Sklodowska-Curie COFUND Action. This program provides co-funding for postdoctoral fellows in Personalised Medicine. Read more about our TopMed10 program here: http://www.ucd.ie/topmed10/
SFI Research Infrastructure
SBI was part of a team who recently succeeded in obtaining an SFI research infrastructure grant. This award will enable a Comprehensive Molecular Analysis Platform (CMAP) in UCD. Further information on how external users can access the use of this equipment will follow shortly.
Industry Engagement & Business Development
Our researchers are experts in generation, analysis and interpretation of ‘omics’ data (metabolomics, proteomics, transcriptomics, genomics) and integration of this information into predictive computational models. We frequently collaborate with national and international companies, including the following:
Quotes from our Collaborators
“It’s always a pleasure fostering these exchanges between EMBL scientists and colleagues at leading institutes like SBI.”
~ Iain Mattaj, Director General, EMBL
~ Anthony McCauley, Head of Research, Fujitsu
If your organisation generates large amounts of experimental data or if you are interested in leveraging publically available ‘omics’ data to complement your core business activities then our team can help. Individual researchers or teams are available to assist with ‘omics’ data generation, integration of existing warehoused data into predictive models or to advise on infrastructural requirements for planned ‘omics’ initiatives.